2-苯基-1H-咪唑并[1,2-c]嘧啶-5-酮 | 54535-54-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-苯基-1H-咪唑并[1,2-c]嘧啶-5-酮
• 英文名称: 2-phenylimidazo[1,2-c]pyrimidin-5-one
• 英文别名: 2-Phenylimidazo<1,2-c>pyrimidin-5(6H)-on；2-phenyl-6H-imidazo[1,2-c]pyrimidin-5-one；2-Phenylimidazo[1,2-c]pyrimidin-5(1H)-one；2-phenyl-6H-imidazo[1,2-c]pyrimidin-5-one
• CAS: 54535-54-5
• 化学式: C₁₂H₉N₃O
• 分子量: 211.223
• InChiKey: TZYYQMDXTHSYMO-UHFFFAOYSA-N

物化性质

• 密度：
  1.33±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  46.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  胞嘧啶 、 2-溴苯乙酮 以 甲醇 为溶剂， 反应 42.0h， 以35%的产率得到2-苯基-1H-咪唑并[1,2-c]嘧啶-5-酮
  参考文献：
  名称：

  [EN] NOVEL FUSED PYRIMIDINONE AND TRIAZINONE DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTIC USES AS ANTIFUNGAL AND/OR ANTIPARASITIC AGENTS
  [FR] NOUVEAUX DÉRIVÉS DE PYRIMIDINONE ET DE TRIAZINONE FUSIONNÉS, LEUR PROCÉDÉ DE PRÉPARATION ET LEURS UTILISATIONS THÉRAPEUTIQUES EN TANT QU'AGENTS ANTIFONGIQUES ET/OU ANTIPARASITAIRES

  摘要：

  这项发明涉及公式（I）的新型融合嘧啶酮和三嗪酮衍生物，它们的制备方法以及它们作为抗真菌或抗寄生虫药剂的用途。

  公开号：

  WO2017020944A1

文献信息

• Compsoitions and methods for treating epithelia and retinal tissue diseases
  申请人：——

  公开号：US20030008834A1

  公开（公告）日：2003-01-09

  The present invention relates to mononucleoside phosphate compounds that have the benefits of a dinucleotide pharmaceutical. These mononucleoside phosphates can be made from a mononucleotide that has been modified by attaching a degradation resistant substituent on the terminal phosphate of a polyphosphate mononucleotide. By attaching this degradation resistant substituent, the stability from degradation matches or exceeds those of certain dinucleotides.

  本发明涉及具有二核苷酸药物益处的单核苷酸磷酸化合物。这些单核苷酸磷酸酯可以由经过修饰的单核苷酸制成，通过在多磷酸单核苷酸的末端磷酸上连接一个耐降解取代基。通过连接这种耐降解取代基，降解稳定性与某些二核苷酸相匹配或超过。
• Compositions and methods for treating epithelial and retinal tissue diseases
  申请人：Inspire Pharmaceuticals, Inc.

  公开号：EP2647382A1

  公开（公告）日：2013-10-09

  The present invention relates to mononucleoside phosphate compounds that have the benefits of a dinucleotide pharmaceutical. These mononucleoside phosphates can be made from a mononucleotide that has been modified by attaching a degradation resistant substituent on the terminal phosphate of a polyphosphate mononucleotide. By attaching this degradation resistant substituent, the stability from degradation matches or exceeds those of certain dinucleotides.

  本发明涉及具有二核苷酸药物优点的磷酸单核苷化合物。这些单核苷磷酸盐可以由单核苷酸制成，这种单核苷酸是通过在多磷酸单核苷酸的末端磷酸上附加抗降解取代基而修饰的。通过附加这种抗降解取代基，其抗降解稳定性可达到或超过某些二核苷酸。
• Fused pyrimidinone and triazinone derivatives containing bridged nitrogen, their process of preparation and their therapeutic uses as antifungal and/or antiparasitic agents
  申请人：UNIVERSITE DE NANTES

  公开号：US10626115B2

  公开（公告）日：2020-04-21

  The present invention concerns novel fused pyrimidinone and triazinone derivatives containing bridged nitrogen, their process of preparation and their use as antifungal or antiparasitic agents.

  本发明涉及含有桥接氮的新型融合嘧啶酮和三嗪酮衍生物、其制备过程以及作为抗真菌剂或抗寄生虫剂的用途。
• COMPOSITIONS AND METHODS FOR TREATING EPITHELIAL AND RETINAL TISSUE DISEASES
  申请人：Inspire Pharmaceuticals, Inc.

  公开号：EP1545555A2

  公开（公告）日：2005-06-29
• NOVEL FUSED PYRIMIDINONE AND TRIAZINONE DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTIC USES AS ANTIFUNGAL AND/OR ANTIPARASITIC AGENTS.
  申请人：Universite de Nantes

  公开号：EP3328862A1

  公开（公告）日：2018-06-06